Stay updated on Azacitidine + Pembrolizumab in AML Clinical Trial
Sign up to get notified when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.

Latest updates to the Azacitidine + Pembrolizumab in AML Clinical Trial page
- Check6 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1%
- Check13 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as the introduction of new medical terms related to acute myeloid leukemia and various chemical compounds. Notably, previous references to acute graft versus host disease and other leukemia types have been removed.SummaryDifference2%
- Check20 days agoChange DetectedThere are no significant changes to the web page content.SummaryDifference0.5%
- Check27 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.5%
- Check34 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check42 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.7%
Stay in the know with updates to Azacitidine + Pembrolizumab in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.